Combining cytochrome P-450 3A4 modulators and cyclosporine or everolimus in transplantation is successful.
Santiago, Chile. In World J Transplant, Jan 2016
Both groups also received tapering steroids, the cytochrome P-450 3A4 (CYP3A4) modulator, ketoconazole 50-100 mg/d, and cyclosporine with C0 targets in the everolimus group of 200-250 ng/mL in 1 mo, 100-125 ng/mL in 2 mo, and 50-65 ng/mL thereafter, and in the azathioprine or MMF group of 250-300 ng/mL in 1 mo, 200-250 ng/mL in 2 mo, 180-200 ng/mL until 3-6 mo, and 100-125 ng/mL thereafter.
Cobicistat: Review of a Pharmacokinetic Enhancer for HIV Infection.
Philadelphia, United States. In Clin Ther, Oct 2015
FINDINGS: Cobicistat is a PK enhancer lacking antiviral activity that, via selective cytochrome P-450 (CYP) 3A inhibition, inhibits the metabolism of certain antiretroviral medications and is used for prolonging their effect.
Assessing pharmacologic and nonpharmacologic risks in candidates for kidney transplantation.
Philadelphia, United States. In Am J Health Syst Pharm, Jun 2015
Key pharmacotherapy-related issues and considerations during the risk assessment process include (1) anticoagulation concerns, (2) cytochrome P-450 isoenzyme-mediated drug interactions, (3) mental health-related medication use, (4) chronic pain-related medication use, (5) medication allergies, (6) use of hormonal contraception and replacement therapy, (7) prior or current use of immunosuppressants, (8) issues with drug absorption, (9) alcohol use, (10) tobacco use, (11) active use of illicit substances, and (12) use of herbal supplements.
Analysis of CYP1A1 and COMT polymorphisms in women with cervical cancer.
São Paulo, Brazil. In Genet Mol Res, 2014
The aim of this case-control study was to obtain a comprehensive panel of genetic polymorphisms present only in genes (cytochrome P-450 1A1 - CYP1A1 and catechol-O-methyl transferase - COMT) within the metabolic pathway of sex steroids and determine their possible associations with the presence or absence of cervical cancer.
[Clinical significance of pharmacogenetics in psychiatry].
In Wiad Lek, 2012
Participation of cytochrome P-450 isoenzymes (including CYP1A2, CYP2C19, CYP2D6, CYP3A4) in the metabolism of psychotropic drugs contributes to risk of adverse interactions, both in pharmacokinetic and pharmacodynamic phase.
Genetic determinants of response to warfarin during initial anticoagulation.
Nashville, United States. In N Engl J Med, 2008
BACKGROUND: Genetic variants of the enzyme that metabolizes warfarin, cytochrome P-450 2C9 (CYP2C9), and of a key pharmacologic target of warfarin, vitamin K epoxide reductase (VKORC1), contribute to differences in patients' responses to various warfarin doses, but the role of these variants during initial anticoagulation is not clear.